RNA標的低分子治療薬の世界市場レポート 2024

RNA標的低分子治療薬の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には36.9%の年間複合成長率（CAGR）で50億9,000万米ドルに成長すると予想されます。予測期間で予想される成長は、精密医療と個別化療法への注目の高まり、RNAバイオマーカー同定の増加、RNA標的の範囲の拡大、RNA治療薬への資金調達と投資の増加、およびその応用などの要因によるものと考えられます。稀な病気。予測期間中に予想される注目すべき動向としては、スクリーニング技術の進歩、アンチセンスオリゴヌクレオチドの優位性、低分子RNAバインダーの開発、神経疾患におけるRNA治療薬の使用、CRISPR-Cas9技術による遺伝子編集の応用などが挙げられます。

がん症例の予想される増加は、RNA標的低分子治療薬市場の成長を促進すると予想されます。がんは、制御されない細胞増殖を特徴とする多様な疾患であり、がんに関連するRNA分子を選択的に標的とするように設計されたRNA標的小分子による治療が必要です。 2022年 1月の米国がん協会の調査によると、米国では2022年に新たに190万人のがん患者が発生し、609,360人ががん関連で死亡すると予想されています。1日平均1,670人の死亡者というこの憂慮すべき統計は、RNAの進歩が緊急に必要であることを強調しています。増加するがん症例と戦うために低分子治療薬をターゲットにしています。

遺伝性疾患の急増により、RNA標的低分子治療薬市場の成長がさらに加速する傾向にあります。個人の遺伝物質の異常または突然変異から生じる遺伝的障害は、RNAを標的とする小分子によって効果的に対処できます。この革新的な分野は、遺伝性疾患、特に反復RNA配列の毒性拡張を伴う疾患の治療において大きな可能性を秘めています。その好例は鎌状赤血球症で、2023年6月のランセット報告書によれば、鎌状赤血球症は世界で41.4%増加し、2021年には774万人に達しました。このデータに例示されている遺伝性疾患の発生率の上昇は、RNA標的低分子治療薬市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のRNA標的低分子治療薬市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• mRNA（メッセンジャーリボ核酸）翻訳モジュレーター
• RNA（リボ核酸）ス価格修飾
• 直接RNA（リボ核酸）ターゲティング
• その他の製品
• 世界のRNA標的低分子治療薬市場、治療適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 肺線維症
• がん
• 神経変性疾患
• 自己免疫
• 炎症性
• その他の治療適応
• 世界のRNA標的低分子治療薬市場、アプリケーション別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 創薬
• 腫瘍学の調査
• 病気の特定
• 世界のRNA標的低分子治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 調査
• 製薬会社およびバイオテクノロジー会社
• その他のエンドユーザー

第7章 地域および国の分析

• 世界のRNA標的低分子治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のRNA標的低分子治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• RNA標的低分子治療薬市場の競合情勢
• RNA標的低分子治療薬市場の企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Sanofi SA
  • AstraZeneca plc
  • Eli Lilly and Company

第31章 その他の大手および革新的な企業

• Amgen Inc.
• Janssen Pharmaceuticals
• Celgene Corporation
• Vertex Pharmaceuticals
• Servier laboratories
• Genentech Inc.
• PTC Therapeutics Inc.
• Arrakis Therapeutics
• Anima Biotech Inc.
• Skyhawk Therapeutics Inc.
• Remix Therapeutics
• Abivax SA
858 Therapeutics
• Eloxx Pharmaceuticals Inc.
• STORM Therapeutics Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

RNA-targeting small molecule therapeutics refer to small molecule drugs that precisely interact with RNA molecules to modify their function or stability. These therapeutics are designed to treat diseases by employing small-molecule drugs that specifically target disease-causing RNA molecules.

The main categories of RNA-targeting small molecule therapeutics include mRNA (messenger ribonucleic acid) translation modulators, RNA (ribonucleic acid) splicing modification, direct RNA (ribonucleic acid) targeting, and others. mRNA translation modulators are substances or factors that influence the process of protein synthesis by altering the efficiency or rate of mRNA translation. These therapeutics are indicated for the treatment of various conditions such as lung fibrosis, cancer, neurodegenerative diseases, autoimmune disorders, inflammatory diseases, and others. Applications include drug discovery, oncology research, and disease identification, and these treatments are utilized by hospitals, research laboratories, pharmaceutical and biotechnology companies, and other healthcare institutions.

The RNA targeting small molecules therapeutics research report is one of a series of new reports from The Business Research Company that provides RNA targeting small molecules therapeutics market statistics, including the RNA targeting small molecules therapeutics industry's global market size, regional shares, competitors with RNA targeting small molecules therapeutics market share, detailed RNA targeting small molecules therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the RNA targeting small molecules therapeutics industry. This RNA-targeting small molecules therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rna targeting small molecules therapeutics market size has grown exponentially in recent years. It will grow from $1.06 billion in 2023 to $1.45 billion in 2024 at a compound annual growth rate (CAGR) of 37.0%. The increase observed in the historical period can be attributed to factors such as advancements in drug discovery and development, the rising prevalence of RNA-related diseases, financial support from government and private funding sources, the growing interest of the pharmaceutical industry in RNA therapeutics, and success stories associated with RNA therapeutics.

The rna targeting small molecules therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.09 billion in 2028 at a compound annual growth rate (CAGR) of 36.9%. The anticipated growth in the forecast period can be attributed to factors such as the increasing focus on precision medicine and personalized therapies, a rise in RNA biomarker identification, an expanding spectrum of RNA targets, growing funding and investments in RNA therapeutics, and their application in rare diseases. Notable trends expected during the forecast period include advancements in screening technologies, the dominance of antisense oligonucleotides, the development of small molecule RNA binders, the use of RNA therapeutics in neurological disorders, and the application of gene editing with CRISPR-Cas9 technology.

The anticipated rise in cancer cases is set to drive the growth of the RNA-targeting small molecule therapeutics market. Cancer, a diverse set of diseases characterized by uncontrolled cell proliferation, necessitates treatment with RNA-targeting small molecules designed to selectively target RNA molecules associated with cancer. As per research from the American Cancer Society in January 2022, the US is expected to witness 1.9 million new cancer cases and 609,360 cancer-related deaths in 2022. This alarming statistic, averaging 1,670 fatalities daily, underscores the imperative need for advancements in RNA-targeting small molecule therapeutics to combat the increasing number of cancer cases.

The surge in genetic disorders is poised to amplify the growth of the RNA-targeting small molecule therapeutics market. Genetic disorders, arising from abnormalities or mutations in an individual's genetic material, can be effectively addressed by RNA-targeting small molecules. This innovative field holds great potential for treating genetic disorders, particularly those involving toxic expansions of repeated RNA sequences. A case in point is sickle cell disease, which, according to a Lancet report in June 2023, witnessed a 41.4% increase globally, reaching 7.74 million in 2021. The rising incidence of genetic disorders, exemplified by this data, fuels the growth of the RNA-targeting small molecule therapeutics market.

The global rise in infectious diseases is anticipated to contribute to the growth of the RNA-targeting small molecule therapeutics market. These diseases, caused by pathogenic microorganisms, are being combated with RNA-targeting small molecules as a promising approach. By binding to specific structures within RNA molecules, these small molecules disrupt RNA function, hindering pathogen replication or virulence. For instance, considering the data from the Office for National Statistics, the increase in COVID-19 infections in England underscores the urgent need for RNA-targeting small molecule therapeutics to address the rising global infectious diseases.

Strategic partnerships have emerged as a significant trend in the RNA-targeting small molecule therapeutics market. Major companies within the market are forming partnerships, forging collaborative efforts to develop innovative products. In June 2022, Otsuka Pharmaceutical Co. Ltd. collaborated with xFOREST Therapeutics Co. Ltd., pooling resources and leveraging xFOREST's Forest technology for systemic small-molecule drug discovery research targeting RNA structures. Similarly, in March 2021, Evotec SE joined forces with Takeda Pharmaceutical Company Limited to undertake collaborative efforts in discovering and developing RNA-targeting small molecules.

In January 2021, Ribometrix, Inc., collaborated with Genentech Inc. to advance RNA-targeted therapeutic small molecules. This partnership between the US-based drug discovery company and Genentech aims to develop small-molecule drugs that modify RNA function by focusing on three-dimensional RNA structures. Genentech Inc. is a US-based biotechnology research company.

Major companies operating in the rna targeting small molecules therapeutics market report are F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Celgene Corporation, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics.

North America was the largest region in the RNA targeting small molecules therapeutics market in 2023. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rna targeting small molecules therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The RNA-targeting small molecule therapeutics market consists of sales of nusinersen, inotersen, givosiran, and patisiran. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

RNA Targeting Small Molecules Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rna targeting small molecules therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rna targeting small molecules therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rna targeting small molecules therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators; RNA (Ribonucleic Acid) Splicing Modification; Direct RNA (Ribonucleic Acid) Targeting; Other Offerings
• 2) By Therapeutic Indication: Lung Fibrosis; Cancer; Neurodegenerative Diseases; Autoimmune; Inflammatory; Other Therapeutic Indications
• 3) By Application: Drug Discovery; Oncology Research; Disease Identification
• 4) By End User: Hospitals; Research Laboratories; Pharmaceutical And Biotechnology Companies; Other End-Users
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bayer AG; Sanofi S.A.; AstraZeneca plc; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. RNA Targeting Small Molecules Therapeutics Market Characteristics

3. RNA Targeting Small Molecules Therapeutics Market Trends And Strategies

4. RNA Targeting Small Molecules Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global RNA Targeting Small Molecules Therapeutics Market Size and Growth

• 5.1. Global RNA Targeting Small Molecules Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global RNA Targeting Small Molecules Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global RNA Targeting Small Molecules Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. RNA Targeting Small Molecules Therapeutics Market Segmentation

• 6.1. Global RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• mRNA (Messenger Ribonucleic Acid) Translation Modulators
• RNA (Ribonucleic Acid) Splicing Modification
• Direct RNA (Ribonucleic Acid) Targeting
• Other Offerings
• 6.2. Global RNA Targeting Small Molecules Therapeutics Market, Segmentation By Therapeutic Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Lung Fibrosis
• Cancer
• Neurodegenerative Diseases
• Autoimmune
• Inflammatory
• Other Therapeutic Indications
• 6.3. Global RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Drug Discovery
• Oncology Research
• Disease Identification
• 6.4. Global RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Research Laboratories
• Pharmaceutical And Biotechnology Companies
• Other End-Users

7. RNA Targeting Small Molecules Therapeutics Market Regional And Country Analysis

• 7.1. Global RNA Targeting Small Molecules Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global RNA Targeting Small Molecules Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market

• 8.1. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China RNA Targeting Small Molecules Therapeutics Market

• 9.1. China RNA Targeting Small Molecules Therapeutics Market Overview
• 9.2. China RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India RNA Targeting Small Molecules Therapeutics Market

• 10.1. India RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan RNA Targeting Small Molecules Therapeutics Market

• 11.1. Japan RNA Targeting Small Molecules Therapeutics Market Overview
• 11.2. Japan RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia RNA Targeting Small Molecules Therapeutics Market

• 12.1. Australia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia RNA Targeting Small Molecules Therapeutics Market

• 13.1. Indonesia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea RNA Targeting Small Molecules Therapeutics Market

• 14.1. South Korea RNA Targeting Small Molecules Therapeutics Market Overview
• 14.2. South Korea RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe RNA Targeting Small Molecules Therapeutics Market

• 15.1. Western Europe RNA Targeting Small Molecules Therapeutics Market Overview
• 15.2. Western Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK RNA Targeting Small Molecules Therapeutics Market

• 16.1. UK RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany RNA Targeting Small Molecules Therapeutics Market

• 17.1. Germany RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France RNA Targeting Small Molecules Therapeutics Market

• 18.1. France RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy RNA Targeting Small Molecules Therapeutics Market

• 19.1. Italy RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain RNA Targeting Small Molecules Therapeutics Market

• 20.1. Spain RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe RNA Targeting Small Molecules Therapeutics Market

• 21.1. Eastern Europe RNA Targeting Small Molecules Therapeutics Market Overview
• 21.2. Eastern Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia RNA Targeting Small Molecules Therapeutics Market

• 22.1. Russia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America RNA Targeting Small Molecules Therapeutics Market

• 23.1. North America RNA Targeting Small Molecules Therapeutics Market Overview
• 23.2. North America RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA RNA Targeting Small Molecules Therapeutics Market

• 24.1. USA RNA Targeting Small Molecules Therapeutics Market Overview
• 24.2. USA RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada RNA Targeting Small Molecules Therapeutics Market

• 25.1. Canada RNA Targeting Small Molecules Therapeutics Market Overview
• 25.2. Canada RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America RNA Targeting Small Molecules Therapeutics Market

• 26.1. South America RNA Targeting Small Molecules Therapeutics Market Overview
• 26.2. South America RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil RNA Targeting Small Molecules Therapeutics Market

• 27.1. Brazil RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East RNA Targeting Small Molecules Therapeutics Market

• 28.1. Middle East RNA Targeting Small Molecules Therapeutics Market Overview
• 28.2. Middle East RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa RNA Targeting Small Molecules Therapeutics Market

• 29.1. Africa RNA Targeting Small Molecules Therapeutics Market Overview
• 29.2. Africa RNA Targeting Small Molecules Therapeutics Market, Segmentation By Offering, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa RNA Targeting Small Molecules Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa RNA Targeting Small Molecules Therapeutics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. RNA Targeting Small Molecules Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. RNA Targeting Small Molecules Therapeutics Market Competitive Landscape
• 30.2. RNA Targeting Small Molecules Therapeutics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bayer AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Sanofi S.A.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Eli Lilly and Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. RNA Targeting Small Molecules Therapeutics Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Janssen Pharmaceuticals
• 31.3. Celgene Corporation
• 31.4. Vertex Pharmaceuticals
• 31.5. Servier laboratories
• 31.6. Genentech Inc.
• 31.7. PTC Therapeutics Inc.
• 31.8. Arrakis Therapeutics
• 31.9. Anima Biotech Inc.
• 31.10. Skyhawk Therapeutics Inc.
• 31.11. Remix Therapeutics
• 31.12. Abivax SA
  • 31.13. 858 Therapeutics
• 31.14. Eloxx Pharmaceuticals Inc.
• 31.15. STORM Therapeutics Ltd.

32. Global RNA Targeting Small Molecules Therapeutics Market Competitive Benchmarking

33. Global RNA Targeting Small Molecules Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The RNA Targeting Small Molecules Therapeutics Market

35. RNA Targeting Small Molecules Therapeutics Market Future Outlook and Potential Analysis

• 35.1 RNA Targeting Small Molecules Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 RNA Targeting Small Molecules Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 RNA Targeting Small Molecules Therapeutics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer